Cancer agents and Electrolyte Disorders • Hypocalcemia: Cisplatin from Low Mg, Cetuximab- due to low Mg Axitinib, Regorafenib • Hypophosphatemia: Ifosfamide - Fanconi syndrome, Imatinib- Secondary Pth, BRAF inhibitors, Sorafenib- vit D mediated, Regorafenib • Hypomaqnesemia: Cisplatin- renal losses, Cetuximab and Panitumumab- renal wasting, Erlotinib, Trastuzumab • Hyponatremia: Cisplatin- renal salt wasting, Bevacizumab, Volociximab-SIADH, Temsirolimus and everolimus- Aldosterone resistance, PD-1 Inhibitors- unknown mechanism, CTLA-4 inhibitors- hypophysitis, Methotrexate- SIADH, Trastuzumab • Hypokalemia: Cisplatin- due to low Mg, Ifosfamide - Fanconi syndrome, Cetuximab- due to low Mg, BRAF inhibitors- fanconi, Methotrexate - ion channel dysfunction, Vandetanib Dr. Kenar Jhaveri @kdjhaveri #Electrolytes #Disorders #Cancer #agents #chemotherapy #diagnosis #differential
